# Thyroid Cancer

Management hinges on histology, anatomic extent, iodine avidity, and recurrence risk. Use ultrasound-directed staging and pathology to select lobectomy versus total thyroidectomy, reserve radioiodine for appropriate differentiated cancers, and avoid DTC algorithms in medullary disease.

**Clinical question:** How should physicians stage, treat, and surveil thyroid cancer according to histology, extent, and treatment response?

Updated: 2026-08-24T16:57:54.607669+00:00

## What matters in practice
- Obtain high-quality thyroid and cervical lymph-node ultrasound in every patient with known or suspected thyroid nodules; use FNA for diagnostic confirmation rather than serum thyroglobulin. [21]
- For low-risk differentiated thyroid cancer smaller than 4 cm, intrathyroidal, and without nodal disease, lobectomy is a guideline-supported de-escalation strategy. [24]
- Clinically apparent lateral-neck nodal metastasis has generally favored total thyroidectomy with neck dissection and radioactive iodine, although selected unilateral cN1b cohorts report similar recurrence and survival after lobectomy plus ipsilateral lateral neck dissection. [2][3]
- Radioiodine and TSH suppression are differentiated-thyroid-cancer strategies; neither is routine therapy for medullary thyroid carcinoma. [5][22]
- After treated differentiated thyroid cancer, trend thyroglobulin and thyroglobulin antibodies, apply risk-based TSH suppression, and escalate to radioiodine or structural imaging when dynamic risk stratification indicates biochemical or structural disease. [11]

## Define histology and regional extent before choosing surgery

The first operative decision depends on tumor type, thyroid extent, and clinically involved nodes.

Perform thyroid ultrasound with a dedicated cervical lymph-node survey for every known or suspected thyroid nodule. The examination confirms the index lesion, identifies contralateral or multifocal nodules, and assesses cervical nodes that may alter the planned operation from thyroid surgery alone to compartment-directed nodal dissection. [21]

Use ultrasound-guided fine-needle aspiration (FNA) to establish malignancy when tissue diagnosis will change management. FNA is the most precise diagnostic test for thyroid nodules and has reduced unnecessary thyroid surgery; serum thyroglobulin should not be used to exclude malignancy because it lacks adequate diagnostic specificity and sensitivity in nodular thyroid disease. [21]

Treat rapid enlargement, dysphagia, neck pain, hoarseness, prior head or neck radiation, and a family history of thyroid cancer or polyposis syndromes as escalation features that warrant careful imaging review and tissue-directed planning rather than routine observation. [21]

When FNA or molecular testing indicates medullary thyroid carcinoma (MTC), do not apply the differentiated thyroid carcinoma (DTC) pathway. MTC arises from parafollicular cells, and molecular testing that strongly suggests MTC can appropriately change the preoperative plan toward total thyroidectomy with central and, when indicated by regional disease, lateral neck dissection. [20]
- Document whether disease is confined to one lobe or is bilateral/multifocal on ultrasound, because unifocal intrathyroidal disease may permit lobectomy whereas bilateral disease changes surgical feasibility. [21][24]
- Map suspicious lateral-neck disease before the initial operation; clinically apparent N1b disease is a major driver of neck-dissection planning. [2][3]

*Histology-directed treatment fork. [5][20][22]*

| Finding | Interpretation | Next treatment consequence |
| --- | --- | --- |
| Papillary or follicular differentiated thyroid carcinoma | Surgery, radioactive iodine, and thyroid-hormone therapy are core disease-directed modalities. [5] | Choose thyroid extent from anatomic risk; consider radioactive iodine and TSH suppression after definitive surgery when indicated. [5][11] |
| Medullary thyroid carcinoma | MTC is not responsive to radioactive iodine or TSH suppression. [5] | Plan surgery as the potentially curative modality; total thyroidectomy with central neck dissection remains the recommended initial approach. [22] |
| Molecular test highly suggestive of MTC | A preoperative molecular result can redirect surgical planning toward total thyroidectomy and central/lateral compartment management. [20] | Avoid a limited operation that does not account for MTC-associated nodal disease. [20] |

## Select lobectomy or total thyroidectomy by anatomic risk and downstream treatment goals

For DTC, surgical extent should balance oncologic control against complication burden and the need for radioiodine-based follow-up.

Offer thyroid lobectomy as a de-escalated surgical option for low-risk DTC that is smaller than 4 cm, confined to the thyroid, and without evidence of cervical nodal spread. This approach preserves contralateral thyroid tissue and avoids the added operative extent of total thyroidectomy in patients unlikely to benefit from routine radioactive iodine. [24]

Use total thyroidectomy when disease extent or planned adjuvant management requires complete gland removal. In intermediate-risk patients with clinically apparent lateral neck metastasis (cN1b), NCCN guidance cited in contemporary surgical literature recommends total thyroidectomy; this is commonly paired with ipsilateral lateral neck dissection and, in usual practice, radioactive iodine. [3][2]

Do not assume that cN1b status mandates the same operation in every patient. Propensity-matched observational cohorts of selected patients with primary tumors limited to one thyroid lobe and ipsilateral lateral neck metastases found no important difference in overall survival or recurrence between lobectomy plus ipsilateral lateral neck dissection and total thyroidectomy-based treatment; these data support multidisciplinary case selection rather than broad replacement of standard total-thyroidectomy pathways. [2][3]

Counsel explicitly about the tradeoff: total thyroidectomy facilitates radioactive iodine administration and thyroglobulin-centered surveillance but has been associated with higher complication rates, higher cost, and lower health-related quality-of-life outcomes than lobectomy in comparative literature. [23]
- For low-risk intrathyroidal tumors under 4 cm without nodal disease, discuss lobectomy as an initial definitive option. [24]
- For clinically evident unilateral lateral-neck metastases, obtain a multidisciplinary surgical plan that addresses both thyroid extent and ipsilateral lateral-neck dissection. [2][3]
- Use institutional surgical expertise when considering lobectomy for N1b disease; the favorable lobectomy data derive from selected tertiary-center cohorts, not randomized trials. [2][3]

*Surgical selection for differentiated thyroid carcinoma. [2][3][24]*

| Clinical pattern | Reasonable operative direction | Decision-limiting consideration |
| --- | --- | --- |
| Small (<4 cm), intrathyroidal DTC without cervical nodal disease | Lobectomy is a guideline-supported less-is-more approach. [24] | Radioactive iodine-based management is less readily available after lobectomy. [24] |
| Clinically apparent lateral-neck metastasis (cN1b) | Total thyroidectomy with ipsilateral lateral neck dissection is the usual guideline-aligned pathway. [3] | Selected unilateral, ipsilateral-only cN1b cohorts had similar outcomes after lobectomy plus ipsilateral lateral neck dissection. [2][3] |
| MTC, including disease suspected preoperatively by molecular testing | Total thyroidectomy with central neck dissection; add lateral neck dissection for regional disease. [20][22] | Do not choose total thyroidectomy solely to enable radioiodine or TSH suppression, because these are not routine MTC treatments. [5][22] |

## Use radioiodine and TSH suppression only for differentiated carcinoma

Adjuvant therapy is histology-specific and must be separated from the operative decision.

In DTC, radioactive iodine is used after surgery to treat residual disease and may be curative in some metastatic cases, although metastatic radioiodine uptake is heterogeneous and cure is achieved in only a minority of patients with metastatic disease. [5] Use treatment planning and follow-up imaging in the context of postoperative risk and evidence of iodine-avid disease rather than treating radioiodine as a universal postoperative intervention. [5][11]

Prescribe levothyroxine for risk-based TSH suppression in treated DTC and reassess the intensity as response-to-therapy category evolves. TSH can stimulate thyroid-cancer-cell growth through its receptor, while excessive long-term suppression has cardiovascular and skeletal tradeoffs; dynamic reassessment is therefore preferable to indefinite uniform suppression. [5][4][11]

In patients receiving sorafenib for locally recurrent or metastatic progressive radioactive-iodine-refractory DTC, the FDA-labeled dose is 400 mg orally twice daily without food. Monitor TSH monthly and adjust thyroid replacement as needed: in the DECISION trial, TSH rose above 0.5 mU/L in 41% of sorafenib-treated patients versus 16% with placebo. [1]

Do not use radioactive iodine or TSH suppression as disease-directed therapy for MTC. For MTC, complete surgical removal offers the principal opportunity for cure, and neck-compartment management is determined by primary and regional disease rather than iodine avidity. [5][22]
- Before initiating sorafenib, confirm the clinical setting is progressive, radioactive-iodine-refractory DTC rather than MTC. [1][5]
- During sorafenib therapy for DTC, check TSH monthly and adjust levothyroxine if suppression is lost. [1]
- Revisit TSH targets when response category improves or structural disease emerges; surveillance intensity and suppression should track dynamic risk. [11]

*Postoperative therapy by histology and disease state. [1][5][11][22]*

| Clinical situation | Treatment role | Required monitoring or constraint |
| --- | --- | --- |
| Resected DTC | Risk-based levothyroxine TSH suppression; consider radioactive iodine according to postoperative disease risk and iodine-avid residual disease. [5][11] | Serial thyroglobulin, thyroglobulin antibodies, and response-adapted imaging guide subsequent management. [11] |
| Progressive radioactive-iodine-refractory DTC | Sorafenib 400 mg orally twice daily without food is FDA-labeled for this setting. [1] | Monitor TSH monthly and adjust thyroid-replacement therapy. [1] |
| MTC after definitive surgery | Neither radioactive iodine nor TSH suppression is routine disease-directed treatment. [5][22] | Use surgery and regional nodal management as the principal curative strategy. [22] |

## Escalate surveillance according to dynamic response, not initial risk alone

Post-treatment follow-up should distinguish biochemical change from structural recurrence.

After treatment for DTC, measure serial thyroglobulin and thyroglobulin antibodies, maintain risk-based TSH suppression, and select radioactive iodine scanning or structural imaging according to dynamic risk stratification. A biochemical signal without localized disease and a structural lesion require different next steps; imaging escalation should be driven by the response category rather than a fixed uniform schedule. [11]

An excellent response permits de-intensification. Once an excellent response is achieved, initial low, intermediate, or high recurrence-risk estimates should be revised downward; reported disease-specific mortality is below 1% in this category, supporting less intensive suppression and investigation when there is no structural abnormality. [11]

Do not automatically intensify surveillance solely for biochemical incomplete response in low- to intermediate-initial-risk DTC. No deaths were reported among patients with biochemical incomplete response followed for up to 10 years in the cited surveillance review; intensify structural evaluation when a significant imaging abnormality is identified rather than treating every biochemical category as imminent structural progression. [11]

When recurrent or persistent structural disease is suspected, use neck ultrasound and, as indicated by prior radioactive-iodine uptake and response category, diagnostic or post-therapy whole-body scanning and cross-sectional imaging. Lack of uptake outside the thyroid bed on a post-treatment scan or absence of disease on recent radioiodine and neck imaging helps define the surveillance context but does not replace longitudinal biomarker trends. [11]
- Trend thyroglobulin and thyroglobulin antibodies together; antibody status is part of the surveillance assessment. [11]
- Reduce TSH suppression and testing burden after excellent response when no structural disease is present. [11]
- Escalate from biochemical surveillance to anatomic localization when ultrasound, radioiodine imaging, or other structural imaging demonstrates a meaningful abnormality. [11]

*Response-adapted surveillance in treated differentiated thyroid cancer. [11]*

| Response pattern | Interpretation | Next action |
| --- | --- | --- |
| Excellent response | Subsequent recurrence risk is very low; reported disease-specific mortality is below 1%. [11] | De-intensify TSH suppression and investigations while continuing appropriate longitudinal follow-up. [11] |
| Biochemical incomplete response without significant structural abnormality | Biochemical abnormality alone does not necessarily justify intensified schedules in low- to intermediate-initial-risk disease. [11] | Continue biomarker-based follow-up and obtain structural imaging when clinically indicated. [11] |
| Structural abnormality or imaging evidence of tumor | This changes the response category from isolated biochemical surveillance to localized disease assessment. [11] | Use neck ultrasound, radioactive iodine scanning, and/or cross-sectional imaging to define extent and guide treatment. [11] |

## References
1. This label may not be the latest approved by FDA. For current ... — www.accessdata.fda.gov — https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021923s022lbl.pdf
2. Thyroid Lobectomy and Neck Dissection for N1b Papillary Thyroid Carcinoma — jamanetwork.com — https://jamanetwork.com/journals/jamaotolaryngology/article-abstract/2842513
3. Lobectomy vs Total Thyroidectomy With Ipsilateral Lateral Neck Dissection for N1b Intermediate-Risk Papillary — jamanetwork.com — https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/2827136
4. Current advance of nanotechnology in diagnosis and treatment for malignant tumors | Signal Transduction and Targeted Therapy — www.nature.com — https://www.nature.com/articles/s41392-024-01889-y
5. Targeted therapies for thyroid tumors | Modern Pathology — www.nature.com — https://www.nature.com/articles/modpathol2010165
6. A Belgian single centre outcome study of radioiodine treatment in adolescents with Graves’ disease | Scientific Reports — www.nature.com — https://www.nature.com/articles/s41598-024-82052-z
7. Enhancing Detection of Medullary Thyroid Cancer in ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S3050915726000251
8. Towards harmonised paediatric thyroid cancer care: adult comparisons and gaps — www.sciencedirect.com — https://www.sciencedirect.com/org/science/article/pii/S1479682125001018
9. Thyroid cancer: ESMO Clinical Practice Guidelines for ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0923753420325552
10. Poorly Differentiated Thyroid Cancer - an overview — www.sciencedirect.com — https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/poorly-differentiated-thyroid-cancer
11. Chapter 6: Risk Stratification and Surveillance in... : Journal of Head & Neck Physicians and Surgeons — journals.lww.com — https://journals.lww.com/jhns/fulltext/2024/12001/chapter_6__risk_stratification_and_surveillance_in.9.aspx
12. International Journal of Surgery — journals.lww.com — https://journals.lww.com/international-journal-of-surgery/citation/9900/a_commentary_on__multicenter_analysis_of.3161.aspx
13. Contribution of I-131 SPECT/CT uptake on the dynamic risk ... — journals.lww.com — https://journals.lww.com/qims/_layouts/15/oaks.journals/downloadpdf.aspx?an=01661528-202504000-00002
14. The efficacy of radioactive iodine for the... : Nuclear Medicine ... — journals.lww.com — https://journals.lww.com/nuclearmedicinecomm/fulltext/2018/12000/the_efficacy_of_radioactive_iodine_for_the.4.aspx?Ppt=Article%7Cnuclearmedicinecomm%3A2018%3A12000%3A00004%7C10.1097%2Fmnm.0000000000000897%7C
15. Iodine thyroid blocking - IRIS — iris.who.int — https://iris.who.int/bitstream/handle/10665/259510/9789241550185-eng.pdf?sequence=1
16. Integrating Genetics and Genomics into Multidisciplinary ... — www.facs.org — https://www.facs.org/media/4dtahfjg/rosen-jennifer-thyroid-genetics-and-genomics.pdf
17. US Fine-Needle Aspiration Biopsy for Thyroid Malignancy — uat.ajnr.org — https://uat.ajnr.org/lookup/external-ref?access_num=10.1148%2Fradiol.2018171074&link_type=DOI
18. I:\Cancer\FORDS\Changes Sept06\Frontmatter0906.wpd — www.facs.org — https://www.facs.org/media/vaapxkng/fordsrevised2007.pdf
19. Effects of COVID-19 — www.facs.org — https://www.facs.org/media/a5cb0rap/august-2022-bulletin.pdf
20. Unexpected Diagnosis of Sporadic Medullary Thyroid Carcinoma | ACS — www.facs.org — https://www.facs.org/for-medical-professionals/news-publications/journals/case-reviews/issues/v3n3/02
21. Approach to Thyroid Nodules: Diagnosis and Treatment - PMC — www.ncbi.nlm.nih.gov — http://www.ncbi.nlm.nih.gov/pmc/articles/10861804?term=
22. Vol 18 Issue 6 p.9-11 |  American Thyroid Association — www.thyroid.org — https://www.thyroid.org/patient-thyroid-information/ct-for-patients/june-2025/vol-18-issue-6-p-9-11
23. Vol 15 Issue 5 p.9-10 |  American Thyroid Association — www.thyroid.org — https://www.thyroid.org/patient-thyroid-information/ct-for-patients/may-2022/vol-15-issue-5-p-9-10
24. Vol 14 Issue 8 p.7-8 |  American Thyroid Association — www.thyroid.org — https://www.thyroid.org/patient-thyroid-information/ct-for-patients/august-2021/vol-14-issue-8-p-7-8

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.